Breaking News Instant updates and real-time market news.

VRNA

Verona Pharma

$5.90

-0.45 (-7.09%)

10:20
05/20/19
05/20
10:20
05/20/19
10:20

Verona Pharma presents expanded analysis of ensifentrine clinical data

Verona Pharma presented clinically relevant findings from its chronic obstructive pulmonary disease clinical trial program with lead product candidate, ensifentrine, at the American Thoracic Society International Conference. Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018. The company said, "The expanded analysis is supportive of the differentiated, dual mechanism of action of ensifentrine, as both a bronchodilator and an anti-inflammatory agent in a single compound. It provides further evidence of the potential for ensifentrine to provide significant symptom benefits to patients." Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown in several previous clinical studies to act both as a bronchodilator and an anti-inflammatory agent in a single compound. It is currently being evaluated in a further Phase 2b clinical trial as an add-on to standard therapy for the maintenance treatment of COPD, with data anticipated around year-end and expected to inform dose selection for Phase 3 trials. Verona Pharma expects to hold an end-of-Phase 2 meeting with the FDA in the first half of 2020 and plans to enter Phase 3 trials in 2020. In addition to advancing the nebulized formulation, Verona Pharma has also developed dry powder inhaler and pressurized metered dose inhaler formulations of ensifentrine. In an ongoing Phase 2 clinical trial, the DPI formulation demonstrated dose-dependent, significant bronchodilation following a single dose, and is currently being evaluated over one week of twice-daily treatment, with top-line data expected in the third quarter this year. The pMDI formulation is planned to enter clinical evaluation in a Phase 2 study in COPD patients later this quarter.

VRNA Verona Pharma
$5.90

-0.45 (-7.09%)

01/14/19
WEDB
01/14/19
NO CHANGE
Target $56
WEDB
Outperform
Wedbush says time to buy Verona Pharma, reaction to 3 day combo Phase 2 overdone
Wedbush analyst analyst is Liana Mousssatos notes that Verona Pharma is developing Ensifentrine as a treatment candidate for respiratory diseases such as COPD, CF and potentially asthma, and multiple exploratory Phase 2 trials for COPD have been conducted with the latest testing this new mechanism on top of dual LAMA/LABA and triple background therapy. The analyst adds that topline results were reported and speculates the negative overreaction in stock value is due to the lack of statistical significance for the primary endpoint. While Moussatos acknowledges that lack of statistical significance is "annoying," she believes it is not a deal-breaker for approval. The analyst sees that while the high dose contributed to the lack of statistical significance for the primary endpoint, the low dose has a consistently positive effect in the various analyses and may be a dose used in a future Phase 3 trial. Moussatos considers the weakness to be a buying opportunity, and reiterates an Outperform rating and $56 price target on the shares.
04/17/19
BTIG
04/17/19
INITIATION
BTIG
Buy
Verona Pharma initiated with a Buy at BTIG
04/17/19
BTIG
04/17/19
INITIATION
Target $17
BTIG
Buy
Verona Pharma initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Verona Pharma with a Buy rating and a price target of $17, citing the company's development of RPL554 for Chronic Obstructive Pulmonary Disease, which he sees as an "enormous and underserved market of about 16M patients in the U.S." The analyst states that while the market for COPD treatment is "crowded with bronchodilators", he sees Verona Phama's "highly active and patient-friendly anti-inflammatory drug like RPL554" as an important advance and looks ahead to its pivotal trial study that may begin later this year.

TODAY'S FREE FLY STORIES

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Hot Stocks
Axalta Coating up 14% after announcing review of strategic alternatives »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:10
06/19/19
06/19
07:10
06/19/19
07:10
General news
FX Update: The dollar has seen moderate softness »

FX Update: The dollar has…

NBRV

Nabriva Therapeutics

$2.11

0.045 (2.18%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Hot Stocks
Nabriva Therapeutics submits Type A Meeting Request to FDA for CONTEPO »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADBE

Adobe

$276.80

1.21 (0.44%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Upgrade
Adobe rating change  »

Adobe upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:08
06/19/19
06/19
07:08
06/19/19
07:08
Hot Stocks
Sorrento Therapeutics CEO to provide updates on CD38 immunotherapies »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTEC

Intec Pharma

$4.78

-0.02 (-0.42%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Hot Stocks
Intec Pharma's Accordion Pill meets primary endpoint in PK study »

Intec Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$1.82

0.13 (7.69%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRB

Seres Therapeutics

$2.61

0.16 (6.53%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Hot Stocks
Seres Therapeutics provides statement regarding FDA safety alert for FMT use »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$60.46

1.205 (2.03%)

07:04
06/19/19
06/19
07:04
06/19/19
07:04
Hot Stocks
Cubic announces sale of commercial properties in San Diego, Orlando for $46M »

Cubic announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$20.56

0.16 (0.78%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Conference/Events
Systemax management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Sep

PLXP

PLx Pharma

$4.93

-0.07 (-1.40%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Hot Stocks
PLx Pharma says 'on track' to file VAZALORE submission by year-end »

PLx Pharma announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDB

MongoDB

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Recommendations
MongoDB analyst commentary  »

MongoDB price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SMLP

Summit Midstream

$6.90

0.13 (1.92%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Downgrade
Summit Midstream rating change  »

Summit Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PT

Pintec Technology

$4.38

-0.04 (-0.90%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Pintec Technology expands partnership with 1an.com »

Pintec Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:02
06/19/19
06/19
07:02
06/19/19
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 6/14 MBA Mortgage…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

, BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Catalent tu purchase Bristol-Myers' manufacturing facility in Italy »

Catalent (CTLT) has…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Axalta Coating initiates review of strategic alternatives »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$25.55

0.01 (0.04%)

07:01
06/19/19
06/19
07:01
06/19/19
07:01
Conference/Events
Regional Management management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 13

    Nov

ADBE

Adobe

$276.80

1.21 (0.44%)

06:58
06/19/19
06/19
06:58
06/19/19
06:58
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.30

2.21 (2.69%)

06:58
06/19/19
06/19
06:58
06/19/19
06:58
Recommendations
Nike analyst commentary  »

Nike survey shows weaker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ADBE

Adobe

$276.80

1.21 (0.44%)

06:57
06/19/19
06/19
06:57
06/19/19
06:57
Recommendations
Adobe analyst commentary  »

Adobe growth to slow over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$374.21

19.31 (5.44%)

06:56
06/19/19
06/19
06:56
06/19/19
06:56
Hot Stocks
Qatar Airways to purchase five additional Boeing 777 Freighters for $1.8B »

Qatar Airways announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

GE

General Electric

$10.42

0.38 (3.78%)

06:54
06/19/19
06/19
06:54
06/19/19
06:54
Recommendations
General Electric analyst commentary  »

General Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.